Advertisement

Topics

Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial.

08:00 EDT 12th April 2019 | BioPortfolio

Summary of "Clinical Predictors of Response to Baclofen in the Treatment of Alcohol use Disorder: Results from the BacALD Trial."

To examine clinical predictors of treatment response to baclofen in patients with alcohol use disorder (AUD).

Affiliation

Journal Details

This article was published in the following journal.

Name: Alcohol and alcoholism (Oxford, Oxfordshire)
ISSN: 1464-3502
Pages:

Links

DeepDyve research library

PubMed Articles [56842 Associated PubMed Articles listed on BioPortfolio]

Total and acylated ghrelin plasma levels as potential long-term response markers in alcohol-dependent patients receiving high-dose of the GABA-B receptor agonist baclofen.

The orexigenic hormone ghrelin is involved in the regulation of food intake and energy balance. Previous findings suggest its involvement in the modulation of mesolimbic reward pathways, thus potentia...

Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study.

Baclofen, a selective γ-aminobutyric acid (GABA) receptor agonist, has emerged as a potential treatment for alcohol use disorder with much unexplained variation in response to treatment efficacy and ...

Objective Continuous Monitoring of Alcohol Consumption for Three Months Among Alcohol Use Disorder Treatment Outpatients.

Transdermal alcohol sensing technology allows for objective continuous monitoring of alcohol use. The purpose of this study was to characterize alcohol consumption measured with this technology among ...

Association between gabapentin receipt for any indication and AUDIT-C scores among clinical sub-populations with and without alcohol use disorder.

Current medications for alcohol use disorder (AUD) have limited efficacy and utilization. Some clinical trials have shown efficacy for gabapentin among treatment-seeking individuals. The impact of gab...

Pharmacokinetics and toxicity of high-dose baclofen in ICU patients.

High-dose baclofen could prove beneficial in patients with unhealthy alcohol use in intensive care units (ICU). However, the pharmacokinetic properties of baclofen are unknown in this population. Our ...

Clinical Trials [15739 Associated Clinical Trials listed on BioPortfolio]

Phone-based Safety Monitoring of Baclofen Prescriptions for Alcohol Use Disorder

BACLOPHONE is a prospective multicenter cohort study, which ensure the monthly phone-based monitoring of 792 patients during their first year of baclofen prescription for alcohol use disor...

Baclofen in Managing Acute Alcohol Withdrawal

The study goal is to investigate whether administration of oral baclofen forms an adequate treatment option in the management of acute alcohol withdrawal. We will compare placebo with dose...

Efficacy of Baclofen in the Treatment of Alcohol Addiction

Intervention to achieve alcohol abstinence represents the most effective treatment for alcoholic patients with liver cirrhosis. However no trials have evaluated the efficacy of anti-cravin...

Observational Study on Patients With Baclofen Treatment for Alcohol-dependence in France

Baclofen is an agonist of the amino-butyricum B (GABA-B) receptor used for a long time in neurology to treat spastic contracture. Several clinical studies have suggested its efficacy in th...

A Study of Baclofen Formulations in Healthy Adults

The purpose of this study is to determine the pharmacokinetics, safety, and tolerability of different baclofen formulations.

Medical and Biotech [MESH] Definitions

Rare autosomal recessive disorder of the urea cycle which leads to the accumulation of argininosuccinic acid in body fluids and severe HYPERAMMONEMIA. Clinical features of the neonatal onset of the disorder include poor feeding, vomiting, lethargy, seizures, tachypnea, coma, and death. Later onset results in milder set of clinical features including vomiting, failure to thrive, irritability, behavioral problems, or psychomotor retardation. Mutations in the ARGININOSUCCINATE LYASE gene cause the disorder.

The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results.

Substances interfering with the metabolism of ethyl alcohol, causing unpleasant side effects thought to discourage the drinking of alcoholic beverages. Alcohol deterrents are used in the treatment of alcoholism.

An acute organic mental disorder induced by cessation or reduction in chronic alcohol consumption. Clinical characteristics include CONFUSION; DELUSIONS; vivid HALLUCINATIONS; TREMOR; agitation; insomnia; and signs of autonomic hyperactivity (e.g., elevated blood pressure and heart rate, dilated pupils, and diaphoresis). This condition may occasionally be fatal. It was formerly called delirium tremens. (From Adams et al., Principles of Neurology, 6th ed, p1175)

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article